---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-269399"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:50:10.578910+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q3 net loss $19.6M ($0.09/shr), cash $619.3M; DDC IND on track

## Summary
- Net loss narrowed to $19.6M from $27.2M YoY; loss per share $0.09 vs $0.12.
- Cash, equivalents and marketable securities totaled $619.3M as of Sept 30, 2023.
- R&D expenses fell to $18.6M from $21.3M, driven by NUV-422 termination and headcount reduction.
- Phase 1 monotherapy and Phase 1b combo studies of NUV-868 (BETi) ongoing in advanced solid tumors.
- IND submission for first Drug-Drug Conjugate candidate expected by year-end 2023.

## SEC filing metadata
- accession: 0001193125-23-269399
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312523269399/0001193125-23-269399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312523269399/d563136d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-269399
- JSON: https://secwatch.observer/filing/0001193125-23-269399.json
- Plain text: https://secwatch.observer/filing/0001193125-23-269399.txt

## Key facts
- Earnings Releases
  Nuvation Bio Inc. reported the third quarter ended September 30, 2023 results: net income net loss of $19.6 million, or $(0.09) per share, EPS $(0.09) per share.
  - Period: the third quarter ended September 30, 2023
  - Net income: net loss of $19.6 million, or $(0.09) per share
  - EPS: $(0.09) per share
  - Result: reported results
  source text: Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312523269399/0001193125-23-269399-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.